IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma
Valentina Folgiero(Bambino Gesù Children's Hospital), Angela Mastronuzzi(Bambino Gesù Children's Hospital)
Cited by 41
Related Papers
Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia
|Oncotarget|2013|108
Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas
|PLoS ONE|2008|52
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors
|Frontiers in Immunology|2023|22
Upfront treatment with <scp>mTOR</scp> inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience
|International Journal of Cancer|2020|19